S&P 500   3,844.54 (-0.22%)
DOW   31,056.13 (-0.38%)
QQQ   325.64 (-0.22%)
AAPL   138.01 (+0.83%)
MSFT   227.26 (+1.02%)
FB   275.21 (+0.86%)
GOOGL   1,901.60 (+0.93%)
AMZN   3,294.08 (-0.39%)
TSLA   839.55 (-0.64%)
NVDA   553.00 (-0.31%)
BABA   258.53 (-0.57%)
CGC   33.39 (-0.51%)
GE   11.14 (+0.63%)
MU   82.71 (-2.71%)
AMD   92.56 (+1.13%)
NIO   61.58 (+5.55%)
T   28.84 (+0.03%)
F   11.43 (-0.87%)
ACB   10.49 (-6.09%)
BA   205.17 (-1.08%)
DIS   172.74 (+0.85%)
NFLX   570.61 (-1.59%)
GILD   67.30 (+0.48%)
S&P 500   3,844.54 (-0.22%)
DOW   31,056.13 (-0.38%)
QQQ   325.64 (-0.22%)
AAPL   138.01 (+0.83%)
MSFT   227.26 (+1.02%)
FB   275.21 (+0.86%)
GOOGL   1,901.60 (+0.93%)
AMZN   3,294.08 (-0.39%)
TSLA   839.55 (-0.64%)
NVDA   553.00 (-0.31%)
BABA   258.53 (-0.57%)
CGC   33.39 (-0.51%)
GE   11.14 (+0.63%)
MU   82.71 (-2.71%)
AMD   92.56 (+1.13%)
NIO   61.58 (+5.55%)
T   28.84 (+0.03%)
F   11.43 (-0.87%)
ACB   10.49 (-6.09%)
BA   205.17 (-1.08%)
DIS   172.74 (+0.85%)
NFLX   570.61 (-1.59%)
GILD   67.30 (+0.48%)
S&P 500   3,844.54 (-0.22%)
DOW   31,056.13 (-0.38%)
QQQ   325.64 (-0.22%)
AAPL   138.01 (+0.83%)
MSFT   227.26 (+1.02%)
FB   275.21 (+0.86%)
GOOGL   1,901.60 (+0.93%)
AMZN   3,294.08 (-0.39%)
TSLA   839.55 (-0.64%)
NVDA   553.00 (-0.31%)
BABA   258.53 (-0.57%)
CGC   33.39 (-0.51%)
GE   11.14 (+0.63%)
MU   82.71 (-2.71%)
AMD   92.56 (+1.13%)
NIO   61.58 (+5.55%)
T   28.84 (+0.03%)
F   11.43 (-0.87%)
ACB   10.49 (-6.09%)
BA   205.17 (-1.08%)
DIS   172.74 (+0.85%)
NFLX   570.61 (-1.59%)
GILD   67.30 (+0.48%)
S&P 500   3,844.54 (-0.22%)
DOW   31,056.13 (-0.38%)
QQQ   325.64 (-0.22%)
AAPL   138.01 (+0.83%)
MSFT   227.26 (+1.02%)
FB   275.21 (+0.86%)
GOOGL   1,901.60 (+0.93%)
AMZN   3,294.08 (-0.39%)
TSLA   839.55 (-0.64%)
NVDA   553.00 (-0.31%)
BABA   258.53 (-0.57%)
CGC   33.39 (-0.51%)
GE   11.14 (+0.63%)
MU   82.71 (-2.71%)
AMD   92.56 (+1.13%)
NIO   61.58 (+5.55%)
T   28.84 (+0.03%)
F   11.43 (-0.87%)
ACB   10.49 (-6.09%)
BA   205.17 (-1.08%)
DIS   172.74 (+0.85%)
NFLX   570.61 (-1.59%)
GILD   67.30 (+0.48%)
Log in
NASDAQ:RLMD

Relmada Therapeutics Stock Forecast, Price & News

$36.18
+0.69 (+1.94 %)
(As of 01/22/2021 02:03 PM ET)
Add
Compare
Today's Range
$34.94
Now: $36.18
$36.58
50-Day Range
$31.38
MA: $33.40
$39.28
52-Week Range
$23.25
Now: $36.18
$54.00
Volume2,660 shs
Average Volume74,874 shs
Market Capitalization$587.64 million
P/E RatioN/A
Dividend YieldN/A
Beta0.53
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.

MarketRank

Overall MarketRank

1.08 out of 5 stars

Medical Sector

929th out of 1,921 stocks

Pharmaceutical Preparations Industry

446th out of 769 stocks

Analyst Opinion: 3.4Community Rank: 1.2Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RLMD
CUSIPN/A
CIKN/A
Phone646-876-3459
Employees6

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$7.88 per share

Profitability

Miscellaneous

Market Cap$587.64 million
Next Earnings DateN/A
OptionableOptionable
$36.18
+0.69 (+1.94 %)
(As of 01/22/2021 02:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Relmada Therapeutics (NASDAQ:RLMD) Frequently Asked Questions

How has Relmada Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Relmada Therapeutics' stock was trading at $40.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RLMD shares have decreased by 10.0% and is now trading at $36.18.
View which stocks have been most impacted by COVID-19
.

Is Relmada Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Relmada Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Relmada Therapeutics stock.
View analyst ratings for Relmada Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Relmada Therapeutics?

Wall Street analysts have given Relmada Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Relmada Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Relmada Therapeutics' CEO?

1,448 employees have rated Relmada Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Relmada Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

How were Relmada Therapeutics' earnings last quarter?

Relmada Therapeutics, Inc. (NASDAQ:RLMD) released its earnings results on Tuesday, November, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter.
View Relmada Therapeutics' earnings history
.

What price target have analysts set for RLMD?

4 brokerages have issued 1 year target prices for Relmada Therapeutics' stock. Their forecasts range from $40.00 to $75.00. On average, they expect Relmada Therapeutics' share price to reach $66.25 in the next twelve months. This suggests a possible upside of 83.1% from the stock's current price.
View analysts' price targets for Relmada Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Relmada Therapeutics' key competitors?

Who are Relmada Therapeutics' key executives?

Relmada Therapeutics' management team includes the following people:
  • Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA, CEO & Director (Age 61, Pay $678.23k)
  • Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA, Chief Financial Officer (Age 57, Pay $33.5k)
  • Mr. Charles S. Ence CPA, M.B.A., Chief Accounting & Compliance Officer (Age 56, Pay $290.36k)
  • Ms. Molly Harper, Exec. VP of Operations
  • Dr. Paolo Manfredi M.D., Ph.D., Acting Chief Scientific Officer
  • Ms. Gina DiGuglielmo, VP & Head of Clinical Operations
  • Dr. Marc de Somer M.B.A., M.D., M.P.H., M.Sc., Sr. VP of Clinical Devel.
  • Dr. Marco Pappagallo M.D., Acting Chief Medical Officer
  • Dr. Richard M. Mangano, Consultant (Age 71)

What is Relmada Therapeutics' stock symbol?

Relmada Therapeutics trades on the NASDAQ under the ticker symbol "RLMD."

How do I buy shares of Relmada Therapeutics?

Shares of RLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Relmada Therapeutics' stock price today?

One share of RLMD stock can currently be purchased for approximately $36.18.

How big of a company is Relmada Therapeutics?

Relmada Therapeutics has a market capitalization of $587.64 million. Relmada Therapeutics employs 6 workers across the globe.

What is Relmada Therapeutics' official website?

The official website for Relmada Therapeutics is www.relmada.com.

How can I contact Relmada Therapeutics?

Relmada Therapeutics' mailing address is 880 Third Avenue 12th Floor, NEW YORK NY, 10022. The company can be reached via phone at 646-876-3459 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.